A Phase 1 TP-271 Oral PK Single Ascending Dose Study
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of up to 6 different
single ascending oral doses of TP-271, ranging from 25 mg to 300 mg, in healthy adult male or
female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Tetraphase Pharmaceuticals, Inc.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)